Project 2
项目2
基本信息
- 批准号:10208710
- 负责人:
- 金额:$ 37.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-15 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AtrophicAutoimmunityBehavioralBiologicalBiological MarkersBiologyBrainC9ORF72CharacteristicsClinicalClinical TrialsClinical Trials DesignDataDiseaseDisease ProgressionEnrollmentFrontotemporal Lobar DegenerationsFutureGenesGoalsGoldImageImmunologic MarkersImpaired cognitionImpairmentIndividualInflammationLeadLightLinkLiquid substanceLongitudinal StudiesMagnetic Resonance ImagingMeasurementMeasuresMedical GeneticsMethodsMulti-Institutional Clinical TrialMutationNorth AmericaOutcomeOutcome MeasureParticipantPathologyPatient SelectionPatientsPatternPhenotypePlasmaPopulationProteinsRiskSafetySample SizeSeverity of illnessSurrogate EndpointSyndromeTestingTherapeuticTimebasebehavioral variant frontotemporal dementiaclinical predictorsclinical trial enrollmentdesigndrug developmentgenetic variantimaging biomarkerimmune activationimprovedmolecular pathologymolecular targeted therapiesmotor disordermultimodalityneurofilamentneuropathologypatient populationpatient stratificationpolygenic risk scoreprotein TDP-43rate of changerecruitresponsetau Proteinstherapeutic targettooltreatment effecttrial design
项目摘要
ABSTRACT – ARTFL LEFFTDS Longitudinal FTLD: Project 2
Improvements in understanding the biology of FTLD, combined with revolutionary advancements in drug
development, have created new compounds that can alter the fundamental biological mechanisms that cause
FTLD. FTLD is most commonly associated with either underlying tau (FTLD-tau) or TAR DNA binding protein
43 (FTLD-TDP) brain neuropathology and many new treatments that are now entering clinical trials target one
or the other of these molecular pathologies. This creates a major challenge for designing clinical trials: how to
measure the effects of these new molecularly-targeted therapies in clinically heterogeneous, symptomatic
FTLD populations. The first goal of this project is to develop new clinical tools and surrogate endpoints that can
measure disease progression in heterogeneous FTLD clinical populations. The second goal is to develop
methods to stratify patients at the time of clinical trial enrollment to define populations with more predictable
rates of change or responses to specific therapeutic strategies. We will develop optimized clinical, imaging
and biomarker endpoints for symptomatic FTLD clinical trials that could include multiple clinical and genetic
variants with a single molecular pathology (referred to as a basket trial design) or could be deployed in patients
with a common phenotype (standard parallel design) to improve power to detect treatment effects. Longitudinal
clinical, imaging and fluid biomarker data will be collected in a multicenter clinical trial-ready population
representing the full clinical spectrum of FTLD, including both sporadic FTLD (n=600) and symptomatic f-FTLD
(n=167) from the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) consortium,
which constitutes the core group of centers that will support recruitment for FTLD clinical trials in North
America. We will also examine the impact of developing personalized outcomes in a trial by using each
patient's baseline characteristics to predict which measures will decline over time, with a particular emphasis
on maximizing what is most clinically meaningful to that patient. The specific aims are to: (1) identify the best
clinical and MRI-based endpoints to measure efficacy in “basket design” clinical trials that enroll patients
according to predicted underlying protein pathology, (2) develop trial enrichment strategies that combine
multiple baseline characteristics to predict clinical change in FTLD, and (3) investigate inflammation as a
potential late stage therapeutic target in symptomatic FTLD.
摘要- ARTFL LEFFTDS纵向FTLD:项目2
对FTLD生物学理解的提高,以及药物治疗的革命性进展
开发,已经创造了新的化合物,可以改变基本的生物机制,造成
FTLD。FTLD通常与潜在的tau(FTLD-tau)或TAR DNA结合蛋白相关
43(FTLD-TDP)脑神经病理学和许多新的治疗方法,现在正在进入临床试验的目标之一
或者其他的分子病理学。这给临床试验设计带来了一个重大挑战:如何
测量这些新的分子靶向治疗在临床异质性,症状,
FTLD人群。该项目的第一个目标是开发新的临床工具和替代终点,
在异质性FTLD临床人群中测量疾病进展。第二个目标是发展
在临床试验入组时对患者进行分层的方法,
变化率或对特定治疗策略的反应。我们将开发优化的临床,成像
症状性FTLD临床试验的生物标志物终点,可能包括多种临床和遗传学研究。
具有单一分子病理学的变体(称为篮式试验设计)或可在患者中展开
具有共同表型(标准平行设计),以提高检测治疗效果的功效。纵向
将在多中心临床试验就绪人群中收集临床、成像和液体生物标志物数据
代表FTLD的完整临床谱,包括散发性FTLD(n=600)和症状性f-FTLD
(n=167)来自ARTFL LEFFTDS纵向额颞叶变性(ALLFTD)联盟,
这构成了中心的核心小组,将支持北卡罗来纳州FTLD临床试验的招募。
美国参考我们还将研究在试验中使用每种方法开发个性化结果的影响。
患者的基线特征,以预测哪些指标将随着时间的推移而下降,特别强调
最大限度地发挥对患者的临床意义。具体目标是:(1)确定最佳
临床和基于MRI的终点,用于测量入组患者的“篮子设计”临床试验的疗效
根据预测的潜在蛋白质病理学,(2)开发试验富集策略,其联合收割机
多个基线特征来预测FTLD的临床变化,和(3)研究炎症作为一种
症状性FTLD的潜在晚期治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ADAM L. BOXER其他文献
ADAM L. BOXER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ADAM L. BOXER', 18)}}的其他基金
The Alzheimer's Disease Tau Platform Clinical Trial
阿尔茨海默病 Tau 平台临床试验
- 批准号:
10655872 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD)
不同人群年轻发病痴呆症的生物标志物评估 (BEYONDD)
- 批准号:
10670503 - 财政年份:2022
- 资助金额:
$ 37.64万 - 项目类别:
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
Veri-T:Verdiperstat 治疗由潜在 FTLD-TDP 引起的语义变异原发性进行性失语症的 1 期安慰剂对照试验
- 批准号:
10459524 - 财政年份:2021
- 资助金额:
$ 37.64万 - 项目类别:
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
Veri-T:Verdiperstat 治疗由潜在 FTLD-TDP 引起的语义变异原发性进行性失语症的 1 期安慰剂对照试验
- 批准号:
10280622 - 财政年份:2021
- 资助金额:
$ 37.64万 - 项目类别:
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
Veri-T:Verdiperstat 治疗由潜在 FTLD-TDP 引起的语义变异原发性进行性失语症的 1 期安慰剂对照试验
- 批准号:
10677747 - 财政年份:2021
- 资助金额:
$ 37.64万 - 项目类别:
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS 纵向额颞叶变性 (ALLFTD)
- 批准号:
10448100 - 财政年份:2019
- 资助金额:
$ 37.64万 - 项目类别:
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS 纵向额颞叶变性 (ALLFTD)
- 批准号:
10450014 - 财政年份:2019
- 资助金额:
$ 37.64万 - 项目类别:
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS 纵向额颞叶变性 (ALLFTD)
- 批准号:
10228124 - 财政年份:2019
- 资助金额:
$ 37.64万 - 项目类别:
相似海外基金
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
- 批准号:
502578 - 财政年份:2024
- 资助金额:
$ 37.64万 - 项目类别:
B cell development, autoimmunity and immune regulation
B 细胞发育、自身免疫和免疫调节
- 批准号:
MR/Y033701/1 - 财政年份:2024
- 资助金额:
$ 37.64万 - 项目类别:
Research Grant
Applying advanced understanding of CTLA-4 function to optimise therapies for autoimmunity
应用对 CTLA-4 功能的深入理解来优化自身免疫疗法
- 批准号:
MR/Y001273/1 - 财政年份:2024
- 资助金额:
$ 37.64万 - 项目类别:
Research Grant
MUC16 (CA125) mutations promote fibrosis and autoimmunity in systemic sclerosis
MUC16 (CA125) 突变促进系统性硬化症的纤维化和自身免疫
- 批准号:
478933 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Operating Grants
Development of serologic test for early risk stratification of islet autoimmunity in genetically predisposed T1D individuals
开发用于遗传易感性 T1D 个体胰岛自身免疫早期风险分层的血清学检测
- 批准号:
10760885 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
新发自身免疫/纵向免疫系统分析(MONA-LISA)的机制
- 批准号:
10655219 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Autoimmunity-Associated B Cells in Lupus Nephritis
狼疮性肾炎中自身免疫相关的 B 细胞
- 批准号:
10582053 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Heparan sulfate as a platform to boost regulatory T cell suppression of autoimmunity
硫酸乙酰肝素作为增强调节性 T 细胞抑制自身免疫的平台
- 批准号:
490663 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Operating Grants
The interplay of sex hormones and chromosomes dictates pathogenicity in progressive CNS autoimmunity.
性激素和染色体的相互作用决定了进行性中枢神经系统自身免疫的致病性。
- 批准号:
488982 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Operating Grants
Understanding autoimmunity: Why do B cells sometimes attack our tissues instead of protecting us from infections?
了解自身免疫:为什么 B 细胞有时会攻击我们的组织而不是保护我们免受感染?
- 批准号:
2889164 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Studentship